CYTEIR THERAPEUTICS INC (CYT) Stock News

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500, also rose, gaining, 1.32% to 4,454.48.

Mentions: ROOT BXRX RNLX UNCY ...

5 Value Stocks In The Healthcare Sector

What are Value Stocks?

Mentions: NVS SENS LYEL QSI

Biotech’s Drug Flop Turns Into Boon for Investors on Cash Return

A little-known biotech company, Cyteir Therapeutics Inc., is about to notch its best day ever — on the back of plans to dissolve the company.

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

Cyteir Therapeutics downgraded to neutral at BofA on pipeline prioritization (NASDAQ:CYT)

BofA Securities has downgraded Cyteir Therapeutics (CYT) to neutral from buy citing the company's recent decision on a pipeline prioritization to focus on combination therapies.

Cyteir Therapeutics (NASDAQ:CYT) to prioritize development of CYT-0851

Cyteir Therapeutics (CYT) will prioritize clinical development of CYT-0851 and reduce its workforce as part of the prioritization. Read more here.

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

Cyteir Therapeutics Names Adam Veness General Counsel

Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022